# US 2026/0251650 A1 · Lateral flow device for diagnosing alzheimer's disease using the t14 peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0251650 A1
- Document ID: US20260251650A1
- Status: Published application
- Kind: A1
- Application number: 19/109,556
- Filed: 2023-09-01
- Published: 2026-08-27
- Earliest claimed: 2022-09-08
- Applicants: Neuro-Bio Ltd
- Inventors: Susan GREENFIELD; Sara Garcia-Rates
- Web page: https://patentgrep.com/patent/US20260251650A1

## CPC

- C12Q 1/46: involving cholinesterase
- G01N 33/54387: {Immunochromatographic test strips}
- C07K 16/40: against enzymes
- C12Y 301/01007: Acetylcholinesterase (3.1.1.7)
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2800/28: Neurological disorders
- G01N 2800/2821: Alzheimer
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.

## Claims

### Claim 1

A lateral flow method of diagnosing or prognosing a neurodegenerative disorder in a subject, the method comprising using lateral flow to detect, in a sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof, wherein detecting the presence of the peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof in the sample indicates that the test subject has a neurodegenerative disorder, or a pre-disposition thereto or a negative prognosis thereof.

### Claim 2

A lateral flow apparatus, for diagnosing or prognosing neurodegenerative disorder in a subject, the apparatus comprising a lateral flow support for detecting, in a sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof, wherein detection of the peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof corresponds to the subject having a neurodegenerative disorder, or a pre-disposition thereto or a negative prognosis thereof.

### Claim 3 (depends on 1, 2)

A method or apparatus according to either claim 1 or claim 2, comprising prognosing the progression of the neurodegenerative disorder.

### Claim 4

A method or apparatus according to any preceding claim, comprising diagnosing a neurodegenerative disorder.

### Claim 5

A method or apparatus according to any preceding claim, comprising diagnosing pre-symptomatic conditions in the test subject.

### Claim 6

A method or apparatus according to any preceding claim, comprising conducting a clinical trial to monitor the activity or efficacy of a drug administered to the test subject, and preferably determine how much the subject has, or has not, deteriorated since an earlier test.

### Claim 7

A method or apparatus according to any preceding claim, wherein the peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof, is not determined using ELISA.

### Claim 8

A method or apparatus according to any preceding claim, comprising determining the concentration of soluble peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof.

### Claim 9

A method or apparatus according to any preceding claim, comprising means for determining, in the sample obtained from the test subject, the concentration of SEQ ID No: 3, or a variant or fragment thereof, optionally wherein the means for determining, in the sample obtained from the test subject, the concentration of SEQ ID No: 3, or a variant or fragment thereof comprises an anti-T14 antibody or antigen-binding fragment thereof.

### Claim 10

A method or apparatus according to any preceding claim, wherein the sample is nasal discharge or fluid, saliva, blood, venous blood, arterial blood, blood plasma, blood serum, capillary blood, non-venous blood, non-arterial blood, pin-prick blood, spinal fluid, urine, sweat, tears, breast aspirate, prostate fluid, seminal fluid, vaginal fluid, stool, cervical scraping, cytes, amniotic fluid, intraocular fluid, mucous, moisture in breath, animal tissue, cell lysates, tumour tissue, hair, skin, buccal scrapings, lymph, interstitial fluid, nails, bone marrow, cartilage, prions, bone powder, ear wax, or combinations thereof.

### Claim 11 (depends on 10)

A method or apparatus according to claim 10, wherein the sample comprises nasal discharge or nasal fluid.

### Claim 12 (depends on 10)

A method or apparatus according to claim 10, wherein the sample comprises saliva.

### Claim 13 (depends on 10)

A method or apparatus according to claim 10, wherein the sample comprises capillary blood or pin-prick blood.

### Claim 14

A method or apparatus according to any preceding claim, comprising an inhibition lateral flow test.

### Claim 15

A method or apparatus according to any preceding claim, comprising a sandwich lateral flow test.

### Claim 16

A method or apparatus according to any preceding claim, wherein the apparatus comprises an LFT cartridge, which comprises a sample pad onto which the sample is placed, and wherein the LFT cartridge comprises anti-T14 antibodies, which are optionally labelled with a labelling moiety, such as a gold nanoparticle.

### Claim 17 (depends on 16)

A method or apparatus according to claim 16, wherein the LFT cartridge comprises a fixed T14 peptide test line comprising T14 peptide attached thereto and/or wherein the LFT cartridge comprises a control line comprising an anti-species labelled antibody, which is not specific for T14.

### Claim 18 (depends on 17)

A method or apparatus according to claim 17, wherein when the sample comprises T14 peptide, the peptide is captured by the anti-T14 antibody creating a conjugate of T14-antibody, which T14-antibody conjugate is unable to bind to the fixed T14 peptide that is attached to the test line, and wherein anti-T14 antibody that is not bound to sample T14 peptide in the sample flows and binds to the anti-species labelled antibody attached to the control line.

### Claim 19 (depends on 14, 15, 16, 17, 18)

A method or apparatus according to any one of claims 14-18, wherein when the sample does not comprise T14 peptide, no conjugate of T14-antibody is created, and unbound anti-T14 antibody flows and binds to the LFT fixed T14 peptide that is attached to the test line, and to the anti-species antibody control attached to the control line.

### Claim 20 (depends on 15, 16, 17, 18, 19)

A method or apparatus according to any one of claims 15-19, wherein the LFT cartridge comprises a first anti-T14 antibody, which binds to the first epitope on the T14 peptide, and the LFT cartridge comprises a T14 peptide test line comprising a second anti-T14 antibody, which binds to a second epitope on the T14 peptide.

### Claim 21 (depends on 20)

A method or apparatus according to claim 20, wherein the LFT cartridge comprises a control line comprising an anti-species labelled antibody, which is not specific for T14.

### Claim 22 (depends on 20, 21)

A method or apparatus according to claim 20 or 21, wherein when the sample comprises T14 peptide, it is captured by the first anti-T14 antibody thereby creating a conjugate of T14-antibody, which conjugate is itself captured by the second anti-T14 antibody which is attached to the cartridge along the test line, and any additional anti-T14 antibody that has not bound to T14 peptide in the sample flows and binds to the anti-species control affixed to the control line.

### Claim 23 (depends on 20, 21, 22)

A method or apparatus according to any one of claims 20-22, wherein when the sample does not comprise T14 peptide, no conjugate of T14-antibody is created, and unbound first anti-T14 antibody cannot bind to the second T14 antibody, wherein the first anti-T14 antibody flows to and binds the anti-species control affixed to the control line.

### Claim 24

A method or apparatus according to any preceding claim, wherein the method or apparatus is qualitative, semi-quantitative or quantitative.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method or apparatus according to any one of claims 16-24, comprising means for quantitatively measuring the results of the LFT cartridge, optionally wherein the lateral flow cartridge is adapted to be connected to a reader, computer, tablet or smartphone, which runs software for detecting the test line and control line and, based on the concentrations/values of the test line and control line, calculates the concentration of the peptide of SEQ ID No: 3, or a variant or fragment thereof in the sample.

### Claim 26

A method of diagnosing or prognosing a neurodegenerative disorder in a subject, the method comprising detecting, in a nasal discharge, nasal fluid, or a pin-prick blood sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof, wherein detecting the presence of the peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof in the sample indicates that the test subject has neurodegenerative disorder, or a pre-disposition thereto or a negative prognosis thereof.

### Claim 27

A neurodegenerative disorder diagnostic or prognostic apparatus, for diagnosing or prognosing neurodegenerative disorder in a subject, the apparatus comprising means for detecting, in a nasal discharge, nasal fluid, or a pin-prick blood sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof, wherein detection of the peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof corresponds to the subject having a neurodegenerative disorder, or a pre-disposition thereto or a negative prognosis thereof.

### Claim 28 (depends on 26, 27)

A method or apparatus according to either claim 26 or claim 27, comprising an assay adapted to detect the presence and/or absence of the peptide of SEQ ID No: 3, or a variant or fragment thereof in the sample.

### Claim 29 (depends on 28)

A method or apparatus according to claim 28, wherein the assay comprises lateral flow, an immunoassay, a non-immuno-based assay, Western Blot analysis, enzyme-linked immunosorbent assay (ELISA), fluorometric assay, chemiluminescent assay, or radioimmunoassay analyses.

### Claim 30 (depends on 29)

A method or apparatus according to claim 29, wherein the assay comprises lateral flow.

### Claim 31 (depends on 26, 27, 28, 29, 30)

A method or apparatus according to any one of claims 26-30, wherein the concentration of (i) a soluble peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof, and/or of (ii) an aggregated peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof, is determined.

### Claim 32 (depends on 31)

A method or apparatus according to claim 31, wherein the apparatus comprises means for determining, in the sample obtained from the test subject, the concentration of SEQ ID No: 3, or a variant or fragment thereof, optionally wherein the means for determining, in the sample obtained from the test subject, the concentration of SEQ ID No: 3, or a variant or fragment thereof comprises an anti-T14 antibody or antigen-binding fragment thereof.

### Claim 33 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 32)

A method or apparatus according to any one of claims 9-25, or claim 32, wherein the antibody or antigen-binding fragment thereof specifically binds to SEQ ID No: 3, optionally one or more amino acid in SEQ ID No: 11, preferably wherein the antibody or antigen-binding fragment thereof does not bind to SEQ ID No: 2 (i.e. T30), SEQ ID No: 13 (i.e. T15) and/or SEQ ID No: 14 (i.e. Aβ).

### Claim 34

A method or apparatus according to any preceding claim, wherein the concentration of SEQ ID No: 3, or a variant or fragment thereof, in the sample is:
(i) between 0.1 and 1000 ng, or between 0.2 and 750 ng, or between 0.5 and 500 ng per mg protein in the sample;
(ii) between 1 and 400 ng, or between 2 and 300 ng, or between 3 and 200 ng per mg protein in the sample; and/or
(iii) between 4 and 100 ng, or between 5 and 75 ng, between 10 and 50 ng, or between 20 and 40 ng per mg protein in the sample.

### Claim 35

A method or apparatus according to any preceding claim, wherein the subject has, or is suspected of having, a neurodegenerative disease selected from a group consisting of: Alzheimer's disease; Parkinson's disease; Huntington's disease; Motor Neurone disease; Spinocerebellar type 1, type 2, and type 3; Amyotrophic Lateral Sclerosis (ALS); schizophrenia; Lewy-body dementia; and Frontotemporal Dementia.

### Claim 36

A method or apparatus according to any preceding claim, wherein the subject has, or is suspected of having, Alzheimer's Disease.

### Claim 37

A method or apparatus according to any preceding claim, wherein the methods and apparatus are used on a subject:
(i) who is already diagnosed with a neurodegenerative disorder;
(ii) who is symptomatic and showing signs of cognitive decline or dementia; and/or
(iii) who is not suspected of having a neurodegenerative disorder, and is pre-symptomatic.

### Claim 38

A method or apparatus according to any preceding claim, comprising detection of soluble and/or aggregated peptide comprising or consisting of one or more of any of T7-T13 (i.e. SEQ ID No: 4-10).

### Claim 39

A method or apparatus according to any preceding claim, comprising determining the Braak stage of the subject.

### Claim 40 (depends on 39)

A method or apparatus according to claim 39, wherein the subject is any of Braak stage I, II or III, preferably Braak stage I or II.

### Claim 41 (depends on 39, 40)

A method or apparatus according to either claim 39 or 40, comprising:
(a) analysing, in the sample obtained from the test subject, the concentration of the peptide comprising or consisting of SEQ ID No: 3 (T14), or a variant or fragment thereof; and
(b) comparing this concentration with a reference value from a control population of deceased subjects having known Braak stages for concentrations of soluble peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof,
wherein the Braak stage of the living test subject is determined by comparing the concentration of the peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof, with the respective reference value that is associated with a Braak stage.

### Claim 42 (depends on 41)

A method or apparatus according to claim 41, wherein soluble SEQ ID No: 3 (T14), or a variant or fragment thereof is analysed.

### Claim 43 (depends on 42)

A method or apparatus according to claim 42, wherein:
(i) a lower concentration of soluble peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof, compared to the reference value is indicative of Braak stage I;
(ii) a lower concentration of soluble peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof, compared to the reference value is indicative of Braak stage II; and/or
(iii) a lower concentration of soluble peptide comprising or consisting of SEQ ID No: 3, or a variant or fragment thereof, compared to the reference value is indicative of Braak stage III.

### Claim 44

A method or apparatus according to any preceding claim, comprising measuring the rate of cognitive decline by a Mini Mental State Examination (MMSE) score and/or a Preclinical Alzheimer Cognitive Composite (PACC) score.

### Claim 45

A method or apparatus according to any preceding claim, comprising the use of lateral flow to detect of SEQ ID No: 3, or a variant or fragment thereof, in nasal discharge, nasal fluid or saliva, to diagnose or prognose pre-symptomatic Alzheimer's Disease.
